Life science CEOs embedding AI in compliance workflows face regulatory switching costs, not just technical ones, when models change.
You didn't make one big decision to hand control of your compliance workflow to an AI vendor. You made five small ones, and each felt completely reasonable at the time. By the time the model update arrived, the exit cost wasn't a sprint of prompt re-engineering. It was a revalidation programme.
This episode is for CEOs and commercial leaders at life science tools companies who are scaling AI across their teams and have not yet drawn the line between experimental workflow and validated process.
Matt and Jasmine walk through the story of Henry, a composite built from real conversations with life science tool CEOs, who adopted AI-first operations, hit a model deprecation event, and discovered that the productivity gains he had built his headcount decisions on were sitting on infrastructure he did not control. The conversation unpacks the five decisions that created the problem, the control layer architecture that solves it, and the two-column framework every CEO should run this week.
The core idea: embedding AI inside a validated compliance workflow does not make you more productive. It makes you dependent. And the switching cost is not technical. It is regulatory.
- Why each of Henry's five AI adoption decisions felt low-risk and why together they created a structural dependency
- What changes the moment AI enters a GXP-adjacent validated process and why that is a different category of commitment
- What a control layer is, why it matters, and how tools like Open Web UI sit in that role
- How to split every AI tool you use into two buckets: validated process or experimental workflow
- Why the humans who understood the process before AI ran it are not optional infrastructure
- What question to ask before embedding any AI tool in a compliance workflow: if this changed tomorrow, could I swap it in a week?
AI governance life sciences, validated process AI, GXP AI risk, AI infrastructure life science CEO, model deprecation compliance, control layer AI, AI workflow switching costs, life science marketing AI, regulatory AI risk, AI stack governance, life science tools company AI, AI compliance workflow
Subscribe to A Splice of Life Science Marketing for sharp, commercially grounded conversations on strategy, AI, and go-to-market for life science brands.